Floatz logo

Methotrexate

CD4+/CD56+ Hematodermic Neoplasm

Therapeutic Advances in Childhood Leukemia ConsortiumSmall moleculePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

33 Active assets in the CD4+/CD56+ Hematodermic Neoplasm cohort.

Asset / SponsorPhaseRating
Tagraxofusp
French Innovative Leukemia Organisation
Phase 2BB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 2BB
Fludarabine
Fred Hutchinson Cancer Center
Phase 2BB
Cytarabine
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2B
Dexasone
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2B

View all 47 →

Same molecule, other indications

Methotrexate is also rated in:

adult acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 4
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative · Phase 3
78 / 100
View asset →
acute promyelocytic leukemiaDormant
BBB
Indicative · Phase 3
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →